- Home
- PHGE vs FEMY Comparison
PHGE vs FEMY Comparison
Compare PHGE & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- FEMY
- Stock Information
- Founded
- PHGE 2015
- FEMY 2004
- Country
- PHGE Israel
- FEMY United States
- Employees
- PHGE N/A
- FEMY N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- FEMY Medical/Dental Instruments
- Sector
- PHGE Health Care
- FEMY Health Care
- Exchange
- PHGE Nasdaq
- FEMY Nasdaq
- Market Cap
- PHGE 26.5M
- FEMY 24.9M
- IPO Year
- PHGE N/A
- FEMY 2021
- Fundamental
- Price
- PHGE $0.75
- FEMY $1.01
- Analyst Decision
- PHGE Strong Buy
- FEMY Strong Buy
- Analyst Count
- PHGE 2
- FEMY 3
- Target Price
- PHGE $22.50
- FEMY $10.00
- AVG Volume (30 Days)
- PHGE 151.9K
- FEMY 245.5K
- Earning Date
- PHGE 11-14-2024
- FEMY 11-12-2024
- Dividend Yield
- PHGE N/A
- FEMY N/A
- EPS Growth
- PHGE N/A
- FEMY N/A
- EPS
- PHGE N/A
- FEMY N/A
- Revenue
- PHGE N/A
- FEMY $1,260,643.00
- Revenue This Year
- PHGE N/A
- FEMY $135.27
- Revenue Next Year
- PHGE N/A
- FEMY $310.75
- P/E Ratio
- PHGE N/A
- FEMY N/A
- Revenue Growth
- PHGE N/A
- FEMY 15.33
- 52 Week Low
- PHGE $0.62
- FEMY $0.73
- 52 Week High
- PHGE $8.55
- FEMY $2.40
- Technical
- Relative Strength Index (RSI)
- PHGE 36.37
- FEMY 34.33
- Support Level
- PHGE $0.67
- FEMY $0.98
- Resistance Level
- PHGE $0.81
- FEMY $1.18
- Average True Range (ATR)
- PHGE 0.09
- FEMY 0.08
- MACD
- PHGE 0.00
- FEMY -0.03
- Stochastic Oscillator
- PHGE 44.00
- FEMY 4.76
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.